Systemic α1A-adrenoceptor antagonist inhibits neointimal growth after balloon injury of rat carotid artery

2003 ◽  
Vol 284 (1) ◽  
pp. H385-H392 ◽  
Author(s):  
John C. Teeters ◽  
Cauveh Erami ◽  
Hua Zhang ◽  
James E. Faber
Keyword(s):  
Vascular Disease ◽  
In Vivo Studies ◽  
The Novel ◽  
Balloon Injury ◽  
Systemic Hemodynamic ◽  
Adrenoceptor Antagonist ◽  
And Migration ◽  
Wall Injury

Previous in vitro and in vivo studies have shown that norepinephrine, acting through α1A-adrenoceptors, stimulates hypertrophy, proliferation, and migration of vascular smooth muscle cells and adventitial fibroblasts and may contribute to neointimal growth, lumen loss, and inward remodeling caused by iatrogenic wall injury and vascular disease. Our present aim was to determine whether intravenous administration of the α1A-adrenoceptor antagonist KMD-3213, at dosages without systemic hemodynamic effects, inhibits wall growth after injury. Inhibition of α1A-adrenoceptors with 12.8 and 32 μg/kg KMD-3213 had no effect on arterial pressure or renal and hindquarter resistances in anesthetized rats. A second group then received carotid balloon injury and continuous intravenous KMD-3213 at 4 and 10 μg · kg−1 · h−1for 2 wk. Mean, systolic, and diastolic arterial pressures and heart rate of conscious unrestrained rats were unaffected. KMD-3213 reduced neointima growth by ∼30 and 46% at the two doses ( P< 0.01). These data support the novel hypothesis that a direct α1A-adrenoceptor-dependent trophic action of catecholamines is augmented by injury and may contribute significantly to hypertrophic vascular disease.

scholarly journals In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor

2005 ◽  
Vol 3 (3) ◽  
pp. 514-521 ◽  
Author(s):  
E. PERZBORN ◽  
J. STRASSBURGER ◽  
A. WILMEN ◽  
J. POHLMANN ◽  
S. ROEHRIG ◽  
...  
Keyword(s):  
Factor Xa ◽  
In Vivo Studies ◽  
Factor Xa Inhibitor ◽  
The Novel ◽  
Direct Factor ◽  
Antithrombotic Agent

scholarly journals Advanced in Molecular Mechanisms of Atherosclerosis: From Lipids to Inflammation

2018 ◽  
Vol 10 (2) ◽  
pp. 104-22 ◽  
Author(s):  
Anna Meiliana ◽  
Nurrani Mustika Dewi ◽  
Andi Wijaya
Keyword(s):  
Vascular Disease ◽  
Blood Vessels ◽  
Molecular Mechanisms ◽  
Vascular Dysfunction ◽  
In Vivo Studies ◽  
Disease States ◽  
Fibrous Cap ◽  
Plaque Disruption

BACKGROUND: Atherosclerosis is a leading cause of vascular disease worldwide. During the past several decades, landmark discoveries in the field of vascular biology have evolved our understanding of the biology of blood vessels and the pathobiology of local and systemic vascular disease states and have led to novel disease-modifying therapies for patients. This review is made to understand the molecular mechanism of atherosclerosis for these future therapies.CONTENT: Advances in molecular biology and -omics technologies have facilitated in vitro and in vivo studies which revealed that blood vessels regulate their own redox milieu, metabolism, mechanical environment, and phenotype, in part, through complex interactions between cellular components of the blood vessel wall and circulating factors. Dysregulation of these carefully orchestrated homeostatic interactions has also been implicated as the mechanism by which risk factors for cardiopulmonary vascular disease lead to vascular dysfunction, structural remodeling and, ultimately, adverse clinical events.SUMMARY: Atherosclerosis is a heterogeneous disease, despite a common initiating event of apoB-lipoproteins. Despite of acute thrombotic complications, an adequate resolution response is mounted, where efferocytosis prevents plaque necrosis and a reparative scarring response (the fibrous cap) prevents plaque disruption. However, a small percentage of developing atherosclerotic lesions cannot maintain an adequate resolution response, which leading to the formation of clinically dangerous plaques that can trigger acute lumenal thrombosis and tissue ischemiaand infarction.KEYWORDS: atherosclerosis, oxidative stress, inflammation, efferocytosis, foam cells, thrombosis

In vitro hydrodynamics of the Embol-X cannula

Perfusion ◽  
2002 ◽  
Vol 17 (2) ◽  
pp. 153-156 ◽  
Author(s):  
Anja Gerdes ◽  
Thorsten Hanke ◽  
Hans-H Sievers
Keyword(s):  
In Vivo Studies ◽  
Clinical Effects ◽  
Pressure Gradients ◽  
The Novel ◽  
Flow Rates ◽  
Mock Circulation ◽  
Aortic Cannula ◽  
Novel Concept

Background: Prevention of intraoperative plaque dislodgement in patients with atherosclerotic ascending aorta by development of innovative aortic cannula designs gains growing interest in cardiac surgery. To increase knowledge about the hydrodynamics of the innovative Embol-X™ cannula, which includes an intra-aortic filter device targeting at atheromatous emboli capture, was the aim of the present study. Methods: Pressure gradients and back pressures of the Embol-X™ cannula were measured at varying flow rates in a mock circulation and compared with two commonly used single-stream cannulae. Results: At a flow rate of 5.5 l/min, pressure gradients across the Argyle™ and the RMI cannulae were 48% and 62% and back pressures 25% and 47% lower than the corresponding values across the Embol-X™ cannula. Conclusions: The novel concept of integrating a filter device may provide clinical advantages concerning neurologic outcome. Further in vivo studies seem to be desirable to obtain more information concerning the clinical effects of the Embol-X™ cannula hydrodynamics.

scholarly journals Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)

Blood ◽  
2006 ◽  
Vol 109 (4) ◽  
pp. 1669-1677 ◽  
Author(s):  
Klaus Podar ◽  
Marc S. Raab ◽  
Jing Zhang ◽  
Douglas McMillin ◽  
Iris Breitkreutz ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Xenograft Model ◽  
Multidrug Resistant ◽  
The Novel ◽  
Pkc Inhibitor ◽  
Downstream Signaling ◽  
Synergistic Cytotoxicity ◽  
And Migration

Abstract In multiple myeloma (MM) protein kinase C (PKC) signaling pathways have been implicated in cell proliferation, survival, and migration. Here we investigated the novel, orally available PKC-inhibitor enzastaurin for its anti-MM activity. Enzastaurin specifically inhibits phorbol ester–induced activation of PKC isoforms, as well as phosphorylation of downstream signaling molecules MARCKS and PKCμ. Importantly, it also inhibits PKC activation triggered by growth factors and cytokines secreted by bone marrow stromal cells (BMSCs), costimulation with fibronectin, vascular endothelial growth factor (VEGF), or interleukin-6 (IL-6), as well as MM patient serum. Consequently, enzastaurin inhibits proliferation, survival, and migration of MM cell lines and MM cells isolated from multidrug-resistant patients and overcomes MM-cell growth triggered by binding to BMSCs and endothelial cells. Importantly, strong synergistic cytotoxicity is observed when enzastaurin is combined with bortezomib and moderate synergistic or additive effects when combined with melphalan or lenalidomide. Finally, tumor growth, survival, and angiogenesis are abrogated by enzastaurin in an in vivo xenograft model of human MM. Our results therefore demonstrate in vitro and in vivo efficacy of the orally available PKC inhibitor enzastaurin in MM and strongly support its clinical evaluation, alone or in combination therapies, to improve outcome in patients with MM.

MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies

2015 ◽  
Vol 363 (2) ◽  
pp. 127-136 ◽  
Author(s):  
Kuan-Lin Kuo ◽  
I-Lin Ho ◽  
Chung-Sheng Shi ◽  
June-Tai Wu ◽  
Wei-Chou Lin ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
In Vivo Studies ◽  
And Migration ◽  
Novel Protein ◽  
Proliferation And Migration

scholarly journals The novel role of circular RNA ST3GAL6 on blocking gastric cancer malignant behaviors through autophagy regulated by the FOXP2/MET/mTOR axis

2021 ◽  
Author(s):  
Penghui Xu ◽  
Xing Zhang ◽  
Jiacheng Cao ◽  
Jing Yang ◽  
Zetian Chen ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Circular Rna ◽  
Circular Rnas ◽  
The Novel ◽  
Transcriptional Inhibition ◽  
And Migration ◽  
Induced Apoptosis

Abstract Gastric cancer (GC) ranks third in motality among all cancers worldwide. Circular RNAs (circRNAs) play essential roles in the malignant progression and metastasis of gastric cancer. As a transcription factor, FOXP2 is involved in the progression of many tumours. However, the regulation and association between circRNAs and FOXP2 remain to be discovered. In our study, CircST3GAL6 was significantly depressed in GC tissues and cells. circST3GAL6 overexpression inhibited the proliferation, invasion and metastasis of GC cells in vitro and in vivo. Importantly, circST3GAL6 overexpression induced apoptosis and promote autophagy in GC cells. Furthermore, we found that circST3GAL6 sponged miR-300 and subsequently regulated FOXP2. We further revealed that FOXP2 suppressed the activation of the Met/AKT/mTOR axis, a classic pathway that regulates autophagy-mediated proliferation and migration. In summary, our findings revealed that circST3GAL6 functions as a tumour suppressor through the miR-300/FOXP2 axis in GC, regulates apoptosis and autophagy through FOXP2-mediated transcriptional inhibition of the MET axis and may be a biomarker for GC treatment.

scholarly journals Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice

2002 ◽  
Vol 137 (3) ◽  
pp. 369-374 ◽  
Author(s):  
Anna Rizzi ◽  
Daniela Rizzi ◽  
Giuliano Marzola ◽  
Domenico Regoli ◽  
Bjarne Due Larsen ◽  
...  
Keyword(s):  
In Vivo Studies ◽  
The Novel ◽  
Orphanin Fq ◽  
Pharmacological Characterization ◽  
Receptor Ligand

Gene deletion of dopamine β-hydroxylase and α1-adrenoceptors demonstrates involvement of catecholamines in vascular remodeling

2004 ◽  
Vol 287 (5) ◽  
pp. H2106-H2114 ◽  
Author(s):  
Hua Zhang ◽  
Susanna Cotecchia ◽  
Steven A. Thomas ◽  
Akito Tanoue ◽  
Gozoh Tsujimoto ◽  
...  
Keyword(s):  
Wall Stress ◽  
In Vivo Studies ◽  
Wall Thickening ◽  
Lumen Area ◽  
Pharmacological Agents ◽  
Hypertrophic Growth ◽  
The Media ◽  
And Migration

In vitro studies have shown that stimulation of α1-adrenoceptors (ARs) directly induces proliferation, hypertrophy, and migration of arterial smooth muscle cells and adventitial fibroblasts. In vivo studies confirmed these findings and showed that catecholamine trophic activity becomes excessive after experimental balloon injury and contributes to neointimal growth, adventitial thickening, and lumen loss. However, past studies have been limited by selectivity of pharmacological agents. The aim of this study, in which mice devoid of norepinephrine and epinephrine synthesis [dopamine β-hydroxylase (DBH−/−)] or deficient in α1-AR subtypes expressed in murine carotid (α1B-AR−/− and α1D-AR−/−) were used, was to test the hypothesis that catecholamines contribute to wall hypertrophy after injury. At 3 wk after injury of wild-type mice, lumen area and carotid circumference increased significantly, and hypertrophy of media and adventitia was in excess of that needed to restore circumferential wall stress to normal. In DBH−/− and α1B-AR−/− mice, increases in lumen area, circumference, and hypertrophy of the media and adventitia were reduced by 50–91%, resulting in restoration of wall tension to nearly normal (DBH−/−) or normal (α1B-AR−/−). In contrast, in α1D-AR−/− mice, increases in lumen area, circumference, and wall hypertrophy were unaffected and wall thickening remained in excess of that required to return tension to normal. When examined 5 days after injury, proliferation and leukocyte infiltration were inhibited in DBH−/− mice. These studies suggest that the trophic effects of catecholamines are mediated primarily by α1B-ARs in mouse carotid and contribute to hypertrophic growth after vascular injury.

Sign in / Sign up

Export Citation Format

Share Document